1,066
Views
16
CrossRef citations to date
0
Altmetric
Clinical Study

Sclerostin levels in uremic patients: a link between bone and vascular disease

, , , , , , , , , , , , & show all
Pages 759-764 | Received 21 Nov 2015, Accepted 22 Feb 2016, Published online: 22 Mar 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Qiong Xiao, Yun Tang, Haojun Luo, Sipei Chen, Rong Chen, Zhe Yan, Lei Pu, Li Wang, Guisen Li & Yi Li. (2022) Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling. Renal Failure 44:1, pages 1427-1443.
Read now
Thanaa Fathi Moghazy, Moyassar Ahmad Zaki, Noha Said Kandil, Dalia Aly Maharem, Khaled Aly Matrawy, Moataz Ahmad Zaki & Alaa Mohamed Ismail El-Banna. (2019) Serum sclerostin as a potential biomarker of vascular and valvular types of calcification in chronic kidney disease cases with and without maintenance hemodialysis. Alexandria Journal of Medicine 55:1, pages 15-24.
Read now

Articles from other publishers (14)

Luciano Artur Lopes Pereira, Catarina Meng, Manuel Augusto Gonçalves Amoedo, Maria Teresa de Sousa Costa Pinto Ferreira Mendes, Marco Alexandre Mateus Prazeres Marques, João Miguel Machado Dória Frazão & André Luiz Loureiro Weigert. (2023) Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet. Nefrología (English Edition) 43:2, pages 197-203.
Crossref
Luciano Artur Lopes Pereira, Catarina Meng, Manuel Augusto Gonçalves Amoedo, Maria Teresa de Sousa Costa Pinto Ferreira Mendes, Marco Alexandre Mateus Prazeres Marques, João Miguel Machado Dória Frazão & André Luiz Loureiro Weigert. (2023) Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet. Nefrología 43:2, pages 197-203.
Crossref
Thor Ueland, Elisabeth Astrup, Kari Otterdal, Tove Lekva, Jeshina Janardhanan, John A. J. Prakash, Kurien Thomas, Annika E. Michelsen, Pål Aukrust, George M. Varghese & Jan K. Damås. (2021) Secreted Wnt antagonists in scrub typhus. PLOS Neglected Tropical Diseases 15:4, pages e0009185.
Crossref
Adam Kern, Tomasz Stompór, Jolanta Kiewisz, Bartłomiej E. Kraziński, Jacek Kiezun, Marta Kiezun, Jerzy Górny, Ewa Sienkiewicz, Leszek Gromadziński, Dariusz Onichimowski & Jacek Bil. (2021) The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up. Journal of Personalized Medicine 11:3, pages 186.
Crossref
Ludmila Yu. Milovanova, Lidia V. Lysenko (Kozlovskaya), Svetlana Yu. Milovanova, Marina V. Taranova, Vasiliy V. Kozlov, Vladimir A. Reshetnikov, Marina V. Lebedeva, Tatyana V. Androsova, Daria O. Zubacheva & Natalia V. Chebotareva. (2020) Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2–5D. Terapevticheskii arkhiv 92:6, pages 37-45.
Crossref
Antonino Catalano, Federica Bellone, Nunziata Morabito & Francesco Corica. (2020) Sclerostin and Vascular Pathophysiology. International Journal of Molecular Sciences 21:13, pages 4779.
Crossref
Antoine Bouquegneau, Peter Evenepoel, François Paquot, Olivier Malaise, Etienne Cavalier & Pierre Delanaye. (2020) Sclerostin within the chronic kidney disease spectrum. Clinica Chimica Acta 502, pages 84-90.
Crossref
I. ZOFKOVA. (2018) Involvement of Bone in Systemic Endocrine Regulation. Physiological Research, pages 669-677.
Crossref
Valeria Cernaro, Giovanni Tripepi, Luca Visconti, Antonio Lacquaniti, Gaetano Montalto, Adolfo Romeo, Domenica Cimadoro, Giuseppe Costantino, Francesco Torre, Domenico Santoro & Michele Buemi. (2018) Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Population-Based Analysis. Therapeutic Apheresis and Dialysis 22:5, pages 457-468.
Crossref
Marijan Bosevski. (2018) Sclerostin: a biomarker for chronic kidney disease and vascular disease with added or independent value?. International Urology and Nephrology 50:10, pages 1919-1919.
Crossref
Andreja Figurek & Goce Spasovski. (2018) Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?. International Urology and Nephrology 50:10, pages 1863-1870.
Crossref
Pierre Delanaye, François Paquot, Antoine Bouquegneau, Frank Blocki, Jean-Marie Krzesinski, Pieter Evenepoel, Hans Pottel & Etienne Cavalier. (2018) Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrology Dialysis Transplantation 33:8, pages 1404-1410.
Crossref
Gokce Kundakci Gelir, Sule Sengul, Gokhan Nergizoglu, Sehsuvar Ertürk, Neval Duman & Sim Kutlay. (2018) Is Sclerostin Level Associated with Cardiovascular Diseases in Hemodialysis Patients?. Blood Purification 46:2, pages 118-125.
Crossref
Yousuf M. Al Suleimani, Aly M. Abdelrahman, Turan Karaca, Priyadarsini Manoj, Mohammed Ashique, Abderrahim Nemmar & Badreldin H. Ali. (2018) The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice. Biomedicine & Pharmacotherapy 97, pages 1102-1108.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.